Sunday, April 28, 2024 11:40:54 PM
#AdnexusBiotechnologies has recently added a valuable asset to its therapeutics portfolio. #Sanctum Therapeutics' HIV capsid inhibitor has shown promising results in neutralizing HIV, making it a valuable addition to Adnexus' asset portfolio. By combining our expertise with that of the members of the Sanctum team, who have advanced knowledge in chemistry, pharmacology, in-silico methodology, and drug manufacturing, Adnexus will be able to develop valuable therapeutics independently and expand our #AI #drugdiscovery capabilities.
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM